Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commerce/health industry liaison?

This article was originally published in The Gray Sheet

Executive Summary

Former House Speaker Newt Gingrich (R-Ga.), House Energy & Commerce Chair Joe Barton (R-Texas) and other members are discussing possible legislation to create an undersecretary of health within the Commerce Department, Gingrich reports during an April 23 interview with "The Gray Sheet." Healthcare "is, after all, the largest single sector of the economy, so why shouldn't it have representation in foreign trade negotiations, in trying to work up sales overseas, in working out telemedicine, and making sure American products get good prices, and making sure that our intellectual property rights are being protected?" Gingrich, founder of the Washington, D.C.-based Center for Health Transformation, floated the proposal at AdvaMed's annual meeting (1"The Gray Sheet" March 15, 2004, p. 14)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel